Feb 18, 2025 8:00am EST Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
Nov 14, 2024 8:37am EST Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Oct 21, 2024 9:05am EDT Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
Oct 09, 2024 9:18am EDT Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
Aug 14, 2024 4:25pm EDT Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
Aug 07, 2024 8:00am EDT Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
Jun 17, 2024 8:05am EDT Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Jun 05, 2024 8:05am EDT Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
May 20, 2024 8:01am EDT Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
May 15, 2024 8:00pm EDT Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity